Big Data and Pharmacovigilance: Recent Developments and Applications

doi:10.19803/j.1672-8629.2020.05.12

Abstract

Abstract: ObjectiveTo review and summarize the recent developments and applications of big data technology in pharmacovigilance in order to shed light on possible measures for improving the identification of adverse drug events in China. Methods Official documents from developed countries and recent literature were searched to identify, analyze and summarize the status quo and future developments of big data applications in pharmacovigilance. To elucidate the findings, drug-induced liver injury was used as a case study. Results An increasing number of countries are establishing registries and databases, collaboration networks and alliances to support the big data approach to pharmacovigilance. Big data has played a big role not only in the monitoring and analysis of adverse drug events, but also in the establishment of predictive models of adjuvant pharmacovigilance to predict and prevent potential adverse reactions. Conclusion The development paradigm of pharmacovigilance has changed, and the role of big data in pharmacovigilance will become more prominent in the future. For China, we can learn from other countries to make more informed decisions on the strategies for advancing the pharmacovigilance system.

Key words: pharmacovigilance, big data, real world data, drug-induced liver injury

CLC Number:

R951

LI Meng, HU Hao, UNG Oi Lam Carolina. Big Data and Pharmacovigilance: Recent Developments and Applications[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 311-314.

References

[1] Harpaz R, Dumochel W, Shah NH.Big data and adverse drug reaction detection[J]. Clin Pharmacol Ther, 2016,99(3):268-270.
[2] Duggirala H J, Tonning JM, Smith E, et al.Use of data mining at the Food and Drug Administration[J]. J Am Med Inform Assoc,2016,23(2):428-434.
[3] Vilar S, Friedman C, Hripcsak G.Detection of drug-drug interactions through data mining studies using clinical sources,scientific literature and social media[J]. Briefings in bioinformatics,2017, 19(5): 863-877.
[4] World Health Organization.Pharmacovigilance: ensuring the safe use of medicines[R]. Geneva: World Health Organization,2004.
[5] Bourgeois FT, Orenstein L, Ballakur S,et al.Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease[J]. Journal of the American Geriatrics Society,2017, 65(11): 2354-2361.
[6] Zoccali C, Blankestijn PJ, Bruchfeld A, et al.Children of a Lesser God: Exclusion of Chronic Kidney Disease Patients from Clinical Trials[J]. Nephrology Dialysis Transplantation, 2019, 34(7):1112-1114.
[7] Lockett J, Sauma S, Radziszewska B, et al.Adequacy of inclusion of older adults in NIH‐funded phase III clinical trials[J].Journal of the American Geriatrics Society, 2019, 67(2): 218-222.
[8] Zoccali C, Blankestijn PJ, Bruchfeld A, et al.Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials[J]. Nephrology Dialysis Transplantation, 2019,34(7): 1112-1114.
[9] Ristevski B, Chen M.Big data analytics in medicine and healthcare[J]. Journal of integrative bioinformatics, 2018, 15(3):1-5.
[10] Sherman RE, Anderson SA, Dal Pan GJ, et al.Real-world evidence-what is it and what can it tell us?[J].N Engl J Med,2016,375(23):2293-2297.
[11] Woodcock J.Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?[J].Clin Pharmacol Ther,2012, 91(3):378-380.
[12] Hripcsak G, Albers DJ.Next-generation phenotyping of electronic health records[J]. Journal of the American Medical Informatics Association, 2012, 20(1): 117-121.
[13] Wagholikar KB, Sundararajan V, Deshpande AW.Modeling paradigms for medical diagnostic decision support: a survey and future directions[J]. Journal of medical systems, 2012, 36(5):3029-3049.
[14] Sullivan P, Goldmann D.The promise of comparative effectiveness research[J]. Jama, 2011, 305(4): 400-401.
[15] Bate A, Juniper J, Lawton AM,et al.Designing and incorporating a real world data approach to international drug development and use: what the UK offers[J]. Drug Discov Today, 2016,21(3):400-405.
[16] Moore TJ, Furberg CD.Electronic health data for post-market surveillance: a vision not realized[J]. Drug Saf, 2015,38(7):601-610.
[17] Bate A, Pariente A, Hauben M, et al.Quantitative signal detection and analysis in pharmacovigilance[J]. Mann's pharmacovigilance,2014: 331-354.
[18] Uppsala Monitoring Centre. Vigibase webpage[EB/OL].(2017-07-25)[2019-09-30].https://www. who-umc.org/vigibase/vigibase/.
[19] Food and Drug Administration (FDA). Reports received and reports entered into FAERS by year[EB/OL].(2017-07-25)[2019-09-30].https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/reports-received-and-reports-entered-faers-year.